Trial · NCT01059526
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Occurrence of Anaphylaxis or Other Adverse Events Suggestive of Hypersensitivity | Safety Population | Type 1 hypersensitivity | 4 | 95% Confidence Interval 0.6 to 17.6 | participants |
| Occurrence of Anaphylaxis or Other Adverse Events Suggestive of Hypersensitivity | Safety Population | Anaphylaxis per NIAID criteria | 2 | 95% Confidence Interval 0.0 to 10.7 | participants |
| Occurrence of Seroconversion to Anti-ecallantide Antibodies Upon Exposure to KALBITOR. | Safety Population | Seroconversion based on all Ig antibody classes | 6 | 95% Confidence Interval 3.9 to 26.1 | participants |
| Occurrence of Seroconversion to Anti-ecallantide Antibodies Upon Exposure to KALBITOR. | Safety Population | Seroconversion based on IgE to ecallantide | 0 | 95% Confidence Interval NA to NA | participants |
| Occurrence of Seroconversion to Anti-ecallantide Antibodies Upon Exposure to KALBITOR. | Safety Population | Seroconversion based on neutralizing antibodies | 5 | 95% Confidence Interval 2.2 to 22.2 | participants |
| Occurrence of Adverse Events Related to Disordered Coagulation (Hypercoagulability and Hypocoagulability) Upon Exposure to KALBITOR | Safety Population | 0 | 95% Confidence Interval NA to NA | participants | |
| Overall Patient Response Assessment | Patients Naive to KALBITOR | Better | 10 | participants | |
| Overall Patient Response Assessment | Patients Non- Naive to KALBITOR | Better | 15 | participants | |
| Overall Patient Response Assessment | Patients Naive to KALBITOR | Same | 1 | participants | |
| Overall Patient Response Assessment | Patients Non- Naive to KALBITOR | Same | 2 | participants | |
| Overall Patient Response Assessment | Patients Naive to KALBITOR | Worse | 0 | participants | |
| Overall Patient Response Assessment | Patients Non- Naive to KALBITOR | Worse | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01059526/results